Rheumatoid Arthritis Medication Shows Potential Against COVID-19 Inflammation

Recent research indicates that iguratimod, a medication traditionally used to treat rheumatoid arthritis, may effectively combat excessive inflammation caused by COVID-19. This finding is particularly significant as the pandemic has highlighted the dangers of cytokine storms, which can lead to severe multi-organ failures.

The immune response triggered by the SARS-CoV-2 virus can escalate into a harmful cytokine storm, resulting in acute lung injury and respiratory distress. While glucocorticoids are commonly prescribed to manage such inflammatory responses, they also suppress the body's antiviral capabilities, complicating the recovery process for patients.

To explore alternative treatments, a team led by researchers from the Institute of Science Tokyo, in conjunction with the National Institute of Infectious Diseases, focused on iguratimod's potential. In previous studies, the team identified obesity as a key risk factor for severe COVID-19, noting that visceral fat can harbor inflammatory cells that heighten the risk of cytokine storms in infected individuals.

In their study, the researchers utilized a model involving obese mice infected with SARS-CoV-2 to assess the effectiveness of iguratimod. The mice were subjected to a high-fat diet and then infected with a sub-lethal dose of the virus. Drug treatments commenced shortly before infection and continued for four days afterward. The researchers monitored the mice for survival rates and analyzed lung tissue three days post-infection.

The results were promising, with mice treated with iguratimod exhibiting higher survival rates and less lung damage compared to those treated with other anti-inflammatory drugs like dexamethasone. Moreover, the treatment did not compromise the antiviral immune response, which is critical for clearing the virus.

Findings from the study were published in the European Journal of Pharmacology, illuminating the potential for iguratimod to be repurposed as a treatment for severe COVID-19. The researchers noted that while dexamethasone effectively reduced inflammation, it also diminished the body's ability to fight the virus, leading to poorer outcomes among those treated with it.

As iguratimod is already a safe and approved medication for rheumatoid arthritis, further clinical studies are warranted to confirm its efficacy in managing COVID-19-related inflammatory responses. This could pave the way for new therapeutic strategies to enhance survival rates among patients suffering from severe cases of the virus.